These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 20629576

  • 1. Randomized trial of an alternate human papillomavirus vaccine administration schedule in college-aged women.
    Zimmerman RK, Nowalk MP, Lin CJ, Fox DE, Ko FS, Wettick E, Cost G, Hand L, Hayes J, Michaels M.
    J Womens Health (Larchmt); 2010 Aug; 19(8):1441-7. PubMed ID: 20629576
    [Abstract] [Full Text] [Related]

  • 2. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial.
    Neuzil KM, Canh DG, Thiem VD, Janmohamed A, Huong VM, Tang Y, Diep NT, Tsu V, LaMontagne DS.
    JAMA; 2011 Apr 13; 305(14):1424-31. PubMed ID: 21486975
    [Abstract] [Full Text] [Related]

  • 3. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
    Leung TF, Liu AP, Lim FS, Thollot F, Oh HM, Lee BW, Rombo L, Tan NC, Rouzier R, Friel D, De Muynck B, De Simoni S, Suryakiran P, Hezareh M, Folschweiller N, Thomas F, Struyf F.
    Hum Vaccin Immunother; 2015 Apr 13; 11(7):1689-702. PubMed ID: 26062002
    [Abstract] [Full Text] [Related]

  • 4. Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women.
    Iversen OE, Miranda MJ, Ulied A, Soerdal T, Lazarus E, Chokephaibulkit K, Block SL, Skrivanek A, Nur Azurah AG, Fong SM, Dvorak V, Kim KH, Cestero RM, Berkovitch M, Ceyhan M, Ellison MC, Ritter MA, Yuan SS, DiNubile MJ, Saah AJ, Luxembourg A.
    JAMA; 2016 Dec 13; 316(22):2411-2421. PubMed ID: 27893068
    [Abstract] [Full Text] [Related]

  • 5. Randomized controlled trial of two dosing schedules for human papillomavirus vaccination among college age males.
    Lin CJ, Zimmerman RK, Nowalk MP, Huang HH, Raviotta JM.
    Vaccine; 2014 Feb 03; 32(6):693-9. PubMed ID: 24342252
    [Abstract] [Full Text] [Related]

  • 6. Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose.
    Lamontagne DS, Thiem VD, Huong VM, Tang Y, Neuzil KM.
    J Infect Dis; 2013 Oct 15; 208(8):1325-34. PubMed ID: 23901077
    [Abstract] [Full Text] [Related]

  • 7. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.
    Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, Langley JM, Bettinger JA, Singer J, Money D, Miller D, Naus M, Marra F, Young E.
    JAMA; 2013 May 01; 309(17):1793-802. PubMed ID: 23632723
    [Abstract] [Full Text] [Related]

  • 8. Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months.
    Lazcano-Ponce E, Stanley M, Muñoz N, Torres L, Cruz-Valdez A, Salmerón J, Rojas R, Herrero R, Hernández-Ávila M.
    Vaccine; 2014 Feb 03; 32(6):725-32. PubMed ID: 24355090
    [Abstract] [Full Text] [Related]

  • 9. Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years.
    Puthanakit T, Huang LM, Chiu CH, Tang RB, Schwarz TF, Esposito S, Frenette L, Giaquinto C, McNeil S, Rheault P, Durando P, Horn M, Klar M, Poncelet S, De Simoni S, Friel D, De Muynck B, Suryakiran PV, Hezareh M, Descamps D, Thomas F, Struyf F.
    J Infect Dis; 2016 Aug 15; 214(4):525-36. PubMed ID: 26908726
    [Abstract] [Full Text] [Related]

  • 10. Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial.
    Krajden M, Cook D, Yu A, Chow R, Su Q, Mei W, McNeil S, Money D, Dionne M, Palefsky J, Karunakaran K, Kollmann T, Ogilvie G, Petric M, Dobson S.
    Vaccine; 2014 Jan 23; 32(5):624-30. PubMed ID: 24055350
    [Abstract] [Full Text] [Related]

  • 11. Immunogenicity of 2 and 3 Doses of the Quadrivalent Human Papillomavirus Vaccine up to 120 Months Postvaccination: Follow-up of a Randomized Clinical Trial.
    Donken R, Dobson SRM, Marty KD, Cook D, Sauvageau C, Gilca V, Dionne M, McNeil S, Krajden M, Money D, Kellner J, Scheifele DW, Kollmann T, Bettinger JA, Liu S, Singer J, Naus M, Sadarangani M, Ogilvie GS.
    Clin Infect Dis; 2020 Aug 14; 71(4):1022-1029. PubMed ID: 31617568
    [Abstract] [Full Text] [Related]

  • 12. Antibody responses among adolescent females receiving the quadrivalent HPV vaccine series corresponding to standard or non-standard dosing intervals.
    Russell K, Dunne EF, Kemper AR, Dolor RJ, Unger ER, Panicker G, Markowitz LE, Walter EB.
    Vaccine; 2015 Apr 15; 33(16):1953-8. PubMed ID: 25744229
    [Abstract] [Full Text] [Related]

  • 13. Three-Year Follow-up of 2-Dose Versus 3-Dose HPV Vaccine.
    Bornstein J, Roux S, Kjeld Petersen L, Huang LM, Dobson SR, Pitisuttithum P, Diez-Domingo J, Schilling A, Ariffin H, Tytus R, Rupp R, Senders S, Engel E, Ferris D, Kim YJ, Tae Kim Y, Kurugol Z, Bautista O, Nolan KM, Sankaranarayanan S, Saah A, Luxembourg A.
    Pediatrics; 2021 Jan 15; 147(1):. PubMed ID: 33386332
    [Abstract] [Full Text] [Related]

  • 14. Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial.
    Gilca V, Sauvageau C, Panicker G, De Serres G, Ouakki M, Unger ER.
    Vaccine; 2018 Nov 12; 36(46):7017-7024. PubMed ID: 30314913
    [Abstract] [Full Text] [Related]

  • 15. Randomized trial of HPV4 vaccine assessing the response to HPV4 vaccine in two schedules among Peruvian female sex workers.
    Brown B, Blas M, Cabral A, Carcamo C, Gravitt P, Halsey N.
    Vaccine; 2012 Mar 16; 30(13):2309-14. PubMed ID: 22306855
    [Abstract] [Full Text] [Related]

  • 16. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
    Van Damme P, Leroux-Roels G, Simon P, Foidart JM, Donders G, Hoppenbrouwers K, Levin M, Tibaldi F, Poncelet S, Moris P, Dessy F, Giannini SL, Descamps D, Dubin G.
    Vaccine; 2014 Jun 17; 32(29):3694-705. PubMed ID: 24674663
    [Abstract] [Full Text] [Related]

  • 17. Immunogenicity and Safety of a 9-Valent HPV Vaccine.
    Van Damme P, Olsson SE, Block S, Castellsague X, Gray GE, Herrera T, Huang LM, Kim DS, Pitisuttithum P, Chen J, Christiano S, Maansson R, Moeller E, Sun X, Vuocolo S, Luxembourg A.
    Pediatrics; 2015 Jul 17; 136(1):e28-39. PubMed ID: 26101366
    [Abstract] [Full Text] [Related]

  • 18. Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda.
    LaMontagne DS, Mugisha E, Pan Y, Kumakech E, Ssemaganda A, Kemp TJ, Cover J, Pinto LA, Safaeian M.
    Vaccine; 2014 Oct 29; 32(47):6303-11. PubMed ID: 25218297
    [Abstract] [Full Text] [Related]

  • 19. Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine.
    Luxembourg A, Brown D, Bouchard C, Giuliano AR, Iversen OE, Joura EA, Penny ME, Restrepo JA, Romaguera J, Maansson R, Moeller E, Ritter M, Chen J.
    Hum Vaccin Immunother; 2015 Oct 29; 11(6):1313-22. PubMed ID: 25912208
    [Abstract] [Full Text] [Related]

  • 20. Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination.
    Palmroth J, Merikukka M, Paavonen J, Apter D, Eriksson T, Natunen K, Dubin G, Lehtinen M.
    Int J Cancer; 2012 Dec 15; 131(12):2832-8. PubMed ID: 22492244
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.